Abu Dhabi published the Thiqa reimbursement gates for obesity medication in June 2025 and added a covered daily-oral GLP-1 to the programme in April 2026. Together they price what a UAE weight-management clinic is worth.

On 11 June 2025 the Department of Health – Abu Dhabi published and made effective its Thiqa reimbursement policy for obesity medications, DoH/Policy/TRP-OMM/HPS/V1/2025, owned by the Healthcare Payers Sector (DoH policies index; Thiqa obesity-medication reimbursement policy PDF). On 24 April 2026 the same regulator announced that Foundayo (orforglipron), Eli Lilly's daily-oral glucagon-like peptide-1 receptor agonist, would be covered for eligible adults under DoH's Personalised Weight Management Programme, with the initial rollout at Imperial College London Diabetes & Endocrine Centre (ICLDC), and named the UAE the second country worldwide after the United States to approve the treatment (DoH release, 24 April 2026). Read the two together and the valuation of a UAE weight-management clinic is not what the pitch deck says it is.
THE CLINICAL GATES ARE NARROWER THAN THE CASH-PAY PATTERN The Thiqa policy limits eligibility to adults and grades access by BMI with a comorbidity requirement in the middle bands. Coverage sits at BMI 30.0-34.9 or 35.0-39.9 only where the patient carries a named comorbidity — the policy lists the qualifying conditions and does not leave the threshold to prescriber discretion. BMI at or above 40 qualifies without a comorbidity. Prescribing must be by a primary-care physician or a specialist with DoH obesity-management certification; a provider without that credential is not a reimbursable route. For a clinic whose book runs on walk-in prescriptions to a BMI 27-29 aesthetic cohort — a common cash-pay pattern in Dubai and Abu Dhabi — the Thiqa arithmetic reads out only a fraction of that revenue as covered, and the rest as cash and elastic.
THE COVERAGE CLOCK IS FOUR MONTHS, NOT INDEFINITE The policy runs on a 1-month trial plus a 3-month extension. Continuation of coverage after four months requires documented weight loss greater than 5% versus baseline and demonstrated compliance with a lifestyle-change plan; below that threshold the payer stops paying. A maintenance-dose provision applies below BMI 24.9. A revenue model that prices GLP-1 dispensing as an annuity mis-reads the payer rulebook: the policy has an explicit cut-out and it is measured in months, not years. For a diligence read, the continuation rate at the 4-month cross-check is the number that separates the target's underwritten revenue from the covered revenue it can actually keep.
WHAT THE POLICY EXPLICITLY COVERS AND WHAT IT DOES NOT The Thiqa policy names GLP-1 receptor agonists and phentermine-topiramate combinations as the covered pharmacological classes for obesity management. It excludes minors, applies only in adult populations, and structures the entire reimbursement clock around measured efficacy at four months rather than around a fixed course length. Prescribers outside primary-care and specialist obesity-management certification cannot access the covered rails. For a target where the prescribing base is aesthetic or dermatology-led and does not hold obesity-management certification, the reimbursed line is closed; the revenue that remains is cash-pay, competing directly against a state-covered programme where the same molecule may sit at a lower out-of-pocket price for eligible patients.
WHAT A COVERED DAILY-ORAL DOES TO INJECTABLE ECONOMICS Injectable GLP-1s have run the UAE weight-management economics for the past three years. On 24 April 2026 that assumption changed at the margin: DoH announced Foundayo (orforglipron), the first daily-oral GLP-1 receptor agonist to reach coverage in the Personalised Weight Management Programme, initially through ICLDC (DoH release, 24 April 2026). The programme is DoH's own, delivered in collaboration with the Abu Dhabi Public Health Centre, and the coverage is for adults with obesity or overweight with at least one comorbid condition. Initial rollout is single-site by design, not by limitation. For a clinic marketing injectables to a cohort that would otherwise qualify for the programme, an oral option delivered by a state-backed provider with digital monitoring and continuous clinical support is a competing offer that did not exist a year ago. The valuation question is not whether injectable revenue disappears; it is what discount to a multi-year injectable subscription is now the right base case.
WHERE THIS PRICES THE DEAL For a strategic buyer or PE fund modelling a UAE weight-management or aesthetic-clinic acquisition, the two DoH instruments together frame the valuation: the Thiqa policy defines the reimbursed perimeter, the Foundayo announcement adds a covered daily-oral alternative inside that perimeter, and the 4-month continuation gate caps how long any patient stays on covered treatment without demonstrated results. That perimeter can enlarge or contract the addressable market by a material factor depending on the target's clinic mix, prescriber credentials, and BMI distribution. A revenue line that assumes indefinite GLP-1 subscription revenue on an unrestricted patient base is not what the payer is reimbursing, and it should not be what the deal model prices.
The Monday work is finite. Segment the target's GLP-1 revenue by Thiqa eligibility — BMI band, comorbidity status, adult versus adolescent, prescriber credential. Pull the last twelve months of coverage-continuation rates at the 4-month cross-check against the greater-than-5% weight-loss and lifestyle-compliance gate. Rebuild the acquisition case with a covered-versus-cash split, and stress-test it against a covered oral alternative that did not exist twelve months ago. That valuation and diligence work is where our business valuation practice begins.

This brief covers one instrument. The UAE healthcare regulatory tracker carries the full set — DoH, DHA, EDE and the other emirates — with what each one changes and when it takes effect.